Skip to content

By The National Psoriasis Foundation November 3, 2014

Psoriatic arthritis is a long-term condition that causes pain and swelling in the joints. Updated November 3, 2014. National Psoriasis Foundation website. Why does my psoriasis get worse in the winter? A combination of dry air, decreased sunlight exposure, and colder temperatures all contribute to psoriasis getting worse in the winter. Ashish Agarwal November 3, 20142014-11-03T16:56:27+00:002016-01-07T15:45:26+00:00 Psoriasis triggers, Stress Management 3 Comments.

By The National Psoriasis Foundation November 3, 2014 23Department of Dermatology, Mount Sinai School of Medicine, New York, New York. Tired of psoriasis and psoriatic arthritis impacting your life? 014; 3: 212266. To estimate the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade. Red Book Drug Topics. 2014. Last accessed: 6 November 2014.

Cosentyx is also in Phase III development for psoriatic arthritis (PsA) and ankylosing spondylitis (AS); regulatory applications are planned for 2015. Accessed November 2014. The impact of psoriasis on quality of life: Results for a 1998 National Psoriasis Foundation patient membership survey. Specifically, formulary options for biologic use in psoriasis are often based on a product’s market share across multiple indications and resulting rebates. A recent review of patient surveys from the National Psoriasis Foundation over an 8-year period found that the inability to obtain adequate insurance coverage was among the top reasons for under-treatment and patient dissatisfaction for those with moderate-to-severe disease. Accessed November 3, 2015. 2003;349(21):20142022. This post was written for the National Psoriasis Foundation Blog and originally appeared here. Posted: November 3, 2014.

Jama Network

Psoriatic arthritis is another inflammatory disease characterized by psoriasis and episodes of joint pain and stiffness, which can lead to joint damage and progression of the number of joints involved. National Psoriasis Foundation. Accessed November 3, 2014. For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). In the two Phase III programs, PALACE and ESTEEM, the clinical response of OTEZLA was maintained through week 52 across multiple endpoints. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. Documented failure, contraindication, or intolerance to a 3-month trial of any of the disease-modifying antirheumatic drugs (DMARDs) (eg, sulfasalazine, azathioprine, hydroxychloroquine, cyclosporine, methotrexate, anti-tumor necrosis factor agents). Accessed November 3, 2014. Leonardi CL, Kimball AB, Papp KA, et al. National Psoriasis Foundation. Bipartisan Path2Cures Roundtable Takes Texas (November 3, 2014). Psoriasis Forum. 2013;19:107 109. Results of National Psoriasis Foundation survey. National Psoriasis Foundation. (2005, November 17).

Novartis Cosentyx(tm) Is The First Il-17 Inhibitor To Receive Eu Approval For First-line Treatment Of Moderate-to-severe Psoriasis Patients